10 Top Gene Therapy Companies in 2021
Three years ago, the FDA granted landmark approval to the first in vivo gene therapy for treating an inherited eye disease. Luxturna, an AAV2 based gene therapy developed by Spark Therapeutics, bagged regulatory win to treat this eye disease called Leber congenital amaurosis. Since then, the agency has approved Zolgensma, a spinal muscular atrophy treatment, and has given green light to dozens of small and big biotechs to start clinical trials for their gene therapies.
GO Prime with only $1.49 now
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115